12:00 AM
Jul 15, 2002
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MG98: BBG said MOGN started Phase I studies of continuous 2 week infusions of MG98 in undisclosed number of patients. BBG has European rights to MG98 under a Fe

British Biotech plc (LSE:BBG; BBIOY), Oxford, U.K.
MethylGene Inc., Montreal, Quebec
MGI Pharma Inc. (MOGN), Minneapolis, Minn.

Read the full 88 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD